RAD17P1

Across TCGA pan-cancer cohorts, RAD17P1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RAD17P1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where RAD17P1 RNA is repressed in tumor relative to normal tissue. In most cancer types RAD17P1 is over-expressed in tumor, although a few such as LUSC and THCA show the opposite, repressed pattern.

LUSC, BRCA, and THCA are the cancer types where RAD17P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAD17P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Male	II,III,IV	−0.938	<.001	6	view →
BRCA	All	III,IV	+0.796	<.001	6	view →
THCA	All	All	−0.211	<.001	6	view →
COAD	Female	All	−0.223	.033	2	view →
PRAD	All	All	+0.057	.026	2	view →
LIHC	All	All	+0.005	.040	2	view →
STAD	Male	All	+0.291	.046	1	view →
KIRP	Female	All	−0.031	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RAD17P1–LUSC

Open the LUSC breakdown →